Tarsus Pharmaceuticals (TARS) Q3 2026 earnings review
Tarsus sales reach a record, but two deals bring losses
Tarsus sold a record amount of its eyelid-mite eye drop, and two takeovers turned the quarter into a loss. Sales rose 64% from a year ago, and chief executive Bobby Azamian said patients have now received more than one million bottles since launch. The loss came from a one-time charge for research Tarsus bought with its two takeovers. The drug business itself earned a small operating profit. Finance chief Jeff Farrow lifted the full-year sales plan again, by more than in either earlier step this year.
| XDEMVY sales | $194.6 million +64% from a year ago |
|---|---|
| Operating profit, excluding takeover charges | $7.1 million a $14.5 million loss a year ago |
| Net loss | $668.3 million includes a $632.2 million write-off of bought research |
| Full-year sales outlook | Raised to $715-730 million about 60% growth; middle of the range up $27.5 million |
⚖️ Verdict: 🟢 Bullish
The story got better, because demand ran ahead of the company's own plan and Tarsus lifted that plan by its largest step of the year. Pricing helped as well: the release credits part of the growth to better rebate terms, and selling costs took a smaller slice of each dollar of sales. One caution: the two takeovers sent $260 million of cash out the door and carry up to $840 million of future milestone payments. That bill only arrives if the new medicines work, but it lands on top of a research budget that is already rising.
The question now is whether the two retina programmes strengthen Tarsus or stretch it. Approval would hand the company products in the part of eye care its sales team already visits; failure would mean the $632 million charge bought nothing. Farrow put the cost of carrying both to approval at up to $230 million, so next year's research spending shows how fast that bill arrives.
🐂 Bull Case
Record Sales In the Year's Quietest Quarter
XDEMVY is Tarsus's only medicine, an eye drop that kills the Demodex mites behind an itchy, inflamed eyelid. Summer is the slow season in eye care, because doctors take holidays and go to conferences, and the company itself calls July to September "a seasonally softer quarter in prescription eye care".
Sales still reached a record. Chief commercial officer Neera Clase said "weekly prescriptions of XDEMVY reached an all-time high, and that momentum has continued into the fourth quarter". She also reported that the count of doctors writing at least five prescriptions a week rose about 20% over the spring quarter.
- Sales: $194.6 million, 64% above a year ago and 12% above the second quarter
- Repeat courses: about 20% of prescriptions, against the mid-teens earlier this year
- Website actions that signal a patient intends to seek care: up 75%
- Since launch: more than one million bottles dispensed and over $1 billion of sales
The mix matters because finance chief Jeff Farrow describes a business that must "at the start of each quarter, start at 0 and have to drive new scripts". A six-week course brings no recurring revenue, so repeat courses at a fifth of prescriptions give the sales line a floor it lacked a year ago.
What to watch: the repeat-course share, which Farrow now puts in the low 20s rather than at 20%. Should that share keep climbing while new patients arrive at the same pace, each season starts from a higher base and the summer dip gets smaller.
Selling Costs Fell Against Rising Sales
Tarsus built its market with money: television and streaming advertising, a patient-support operation and a field team calling on eye doctors. Those costs sit in selling, general and administrative expenses, the line that has always been bigger than the gross profit it was meant to create.
- Selling and marketing: 39.8% of sales, against 54.5% a year ago
- General and administrative: 46.5% of sales, against 37.0%, almost all of it deal costs
- Overheads and selling costs excluding the $24.1 million of transaction and integration costs and $11.5 million of accelerated share awards: 71.3% of sales, against 91.5%
So the medicine business made money. Strip out every charge tied to the two takeovers and Tarsus earned an operating profit of $7.1 million, by our math, where a year earlier it lost $14.5 million. Advertising bought growth this quarter without growing in step with it.
What to watch: the overhead line in the fourth quarter, which the full-year plan puts near $157 million. A figure at that level would mean costs climbing again from this quarter's underlying $138.6 million, and the operating profit disappearing with them.
The Drug Business Now Pays Its Own Way
Tarsus has funded itself with share sales and a loan since it started, and the eye drop only reached pharmacies in August 2023. The test of a launch is whether the money customers pay covers what the company spends to serve them. For the first nine months of this year it did.
Customers paid $854.2 million of cash against product sales, which left $30.6 million after every bill, against an outflow of $31.8 million in the same months of 2025. Capital spending of $11.1 million, mostly the new Irvine headquarters, still left about $19.5 million of free cash by our math.
That cash is why the company could pay for two takeovers partly from its own pocket rather than only from investors. It also explains why Farrow talks about choosing where to spend: the operating business, not the equity market, now supplies the first slice of each year's budget.
What to watch: the cash flow statement in the annual report, where a fourth quarter carries the $10 million Elanco milestone and the integration bills. Operating cash that holds above zero through that quarter would make this year's turn look structural rather than seasonal.
🐻 Bear Case
The Outlook Spends the Fourth Quarter's Profit
Farrow raised three numbers at once. Sales for 2026 now run to $715-730 million. Overheads and selling costs go to $605-620 million from $545-565 million, and research to $140-155 million from $115-135 million. Clase added $5 million of advertising, taking that budget to about $95 million.
Work the arithmetic forward and the shape of the quarter changes. The sales plan leaves about $209 million for October to December. The cost plans leave roughly $157 million of overheads and $50 million of research, which puts the company back to an operating loss of about $13.6 million by our math.
Farrow frames the spending as a choice the growth has earned, saying XDEMVY's progress is "giving us greater opportunities to invest in Tarsus' future". The arithmetic says something narrower: research takes about 24% of sales in the fourth quarter against 18% in this one, so the record quarter funds trials rather than profit.
What to watch: the research line in February, against the $140-155 million plan. Spending at the top of that range with four programmes running would mean the operating loss widens into 2027, because both new Phase 3 trials start before any of them can earn a dollar.
A $632 Million Write-Off and $840 Million Owed
Tarsus bought iRenix Medical in July and Alkeus Pharmaceuticals in September. Neither owns a product that sells, so accounting rules treat the science as research with no other use. The company wrote off $632.2 million, $81.0 million for iRenix and $551.2 million for Alkeus, "expensed because they have no alternative future use".
The cash side is the part that binds. Tarsus paid $260.4 million for the two, raised $120.1 million by selling shares privately at $56.00 each, and ended September with $309.6 million of cash and securities against $417.3 million at the turn of the year. Shareholders' equity fell to $104.0 million.
Then come the promises. The sellers can earn up to $840 million more if the medicines are approved and sell: $115 million and $375 million for iRenix, $250 million on a first approval and $100 million on a first sale for Alkeus, plus royalties. Tarsus says "the related payments would be significant and would reduce our cash runway".
What to watch: the cash and securities figure in February, and whether Tarsus taps its $100 million open-market share programme. Management calls none of the milestones "probable of becoming payable in the near term", so the first approval would be both the best news and the biggest bill.
Tarsus Halts Its European and Japanese Filings
Most-favoured-nation rules are the American policy of pushing US drug prices down towards the lower prices charged abroad. A company that launches cheaply in Europe can therefore cut what it collects at home. Farrow drew the conclusion: "we have made the decision to defer regulatory filings for TP-03 in Europe and Japan".
A year ago the same company expected a European approval in 2027 and was mapping a Japanese route with regulators. The 10-Q now says Tarsus deferred both "in light of the current implications of the most-favored-nation regulations". Years of formulation and stability work stay on the shelf.
What is left outside America is China, where partner GrandPharma has launched. Tarsus has collected $101.1 million from that deal, all of it upfront payments and milestones, and has never recorded a single dollar of royalty on Chinese sales. The whole peak-sales ambition of $2 billion is a US figure.
What to watch: the first royalty line from China, and any word that the deferral has become permanent. Royalties starting to flow would give the non-US story a number; continued silence leaves one country and one medicine carrying everything.
Risks This Quarter Didn't Answer
Four standing worries got words rather than numbers this quarter. Tarsus now reports an annual outlook instead of quarterly detail, so several figures investors used to check the launch against have simply stopped appearing in the release and the filing.
- Rebates and discounts: no actual figure for a third quarter. Farrow repeated that "we continue to believe 43% to 45% gross to net discount is what we'll see next quarter as well as into next year", while the release credits growth partly to better discounts.
- Bottles dispensed: no quarterly count since the 103,000 reported for the third quarter of 2025, which leaves volume and net price impossible to separate.
- Competition: a rival treats the same eyelid disease with a cream in mid-stage trials. Farrow said "it's going to be a high bar to beat the success of XDEMVY" and offered no comparison data.
- Protection for the new pill: Farrow said gildeuretinol rests on "orphan exclusivity, composition of matter has expired", roughly seven years from approval, against XDEMVY's cover into 2038.
What to watch: the annual report in February, which carries the gross-to-net policy detail and the full risk discussion. A discount rate above 45% would mean this year's volume growth flattered the sales line, and would make the 2027 plan harder to believe.
👓 Other Themes
Two Takeovers Add Two Retina Programmes
Both purchases point at the back of the eye, which the company calls "one of the largest and fastest-growing specialties". IRX-101 is "an investigational ocular antiseptic" meant to cut pain and corneal damage for patients receiving eye injections; its Phase 3 starts in the first half of 2027. Gildeuretinol, a daily pill for Stargardt disease, reads out in 2029.
💲 Other KPIs
Customers are paying faster: receivables of $100.4 million equal 47.5 days of sales, against 56.3 days a year ago and 51.6 days at the turn of the year. Tarsus sells through a handful of specialty pharmacies, so the figure tracks how quickly those few accounts settle.
This is money Tarsus owes insurers and pharmacies out of sales already booked. It grew 13.5% since December while sales rose far faster, which fits the company's statement that discount terms improved rather than worsened. It is the closest reading a reader gets on rebates this quarter.
Up 15.9% since December. Tarsus issued 2.1 million shares in August's private placement, 2.9 million for Alkeus and 0.6 million for iRenix. The weighted-average count used for the loss per share rose 9% from a year ago, and the Alkeus approval milestone may be settled in more shares.
🔮 Guidance
Raised. The plan now runs to $715-730 million of sales this year. That is about 60% above 2025, and by our math it leaves roughly $209 million for the fourth quarter. Farrow put the increase at almost $28 million from the middle of the previous range, the larger of this year's two raises.
Raised. Overheads and selling costs now run to $605-620 million, about 43% above last year. The middle of the range leaves roughly $157 million for the fourth quarter, above this quarter's $138.6 million once deal costs come out. Farrow named variable fees that rise with volume, more advertising and Alkeus integration as the causes.
Raised. Research now runs to $140-155 million, more than double last year's $64.3 million. The middle leaves about $50 million for the fourth quarter. Two trials read out in the first half of 2027 and two Phase 3 studies begin, and Farrow sized the cost of taking gildeuretinol to approval at "$150 million to $200 million".
Raised. Clase said the team is "adding $5 million to our DTC spend, bringing our full year investment to approximately $95 million". A year ago the company planned about $80 million for 2026. Even so, advertising falls to roughly 13% of sales from 18% last year, because sales have grown faster than the budget.
Unchanged. Farrow expects the same 43% to 45% band next quarter and through 2027, and said the first quarter usually sits at the high end before improving. Tarsus no longer publishes the actual rate, so readers get a range rather than a reading, and the release credits part of this quarter's growth to better discount terms.
❓ Key Questions
What is the discount rate now?
Tarsus stopped publishing what it gives up in rebates and fees when it moved to annual outlooks. It credits part of this quarter's growth to better terms, so the figure decides whether price or volume drove the record.
How many bottles did patients get this quarter?
The last quarterly count was 103,000, for the third quarter of 2025. Without it, nobody outside the company can tell how much of 64% growth came from more patients and how much from net price.
What does 2027 spending look like?
Farrow said next year's assumptions are still being worked through, with advertising somewhere in an $80-95 million range. Two Phase 3 trials start in the first half, so the research line could rise again from this year's raised level.
How would Tarsus pay a $250 million milestone?
The approval milestone for gildeuretinol can be settled in cash or shares at the company's choice. With $309.6 million of cash and securities and a $75 million loan outstanding, either route costs existing holders. Management has not said which it prefers.
Is the Europe and Japan deferral permanent?
Tarsus shelved both filings over US pricing rules after years of preparation. Management has not said what would restart them, or what the delay does to a peak-sales ambition that it already describes as a US-only figure.